title: Use of recombinant factor VIIa (NovoSeven) in patients with Glanzmann thrombasthenia.
abstract: Recombinant factor VIIa (rFVIIa; NovoSeven, Novo Nordisk, Bagsvaerd, Denmark) appears effective and relatively safe for the treatment of bleeding and for surgical prophylaxis in patients with Glanzmann thrombasthenia as reported to the International Registry on rFVIIa and Congenital Platelet Disorders. One of the shortcomings of the Registry data is the heterogeneity of treatment protocol, including dosage, number of doses used, duration of treatment before declaration of failure, and mode of rFVIIa administration (bolus v continuous infusion). The data are not yet sufficient to define optimal regimens for various indications such as the type of bleeding or the type of procedures. The place of this drug compared to platelet transfusion in the overall management of patients with Glanzmann thrombasthenia will need to be determined in relationship to a number of challenges and unresolved issues in the clinical care of these patients. These issues include: how to improve local measures for patients with mucosal bleeds, optimal management of young women during menarche, optimal platelet transfusion regimens for various indications, the relationship between antiplatelet antibodies detected by monoclonal antibody-specific immobilization of platelet antigens (MAIPA) and effectiveness of platelet transfusion, whether there are other biological tests that may correlate with effectiveness of platelet transfusion, and management of pregnancy and delivery regarding antiplatelet immunization.
authors.affiliation: Hemophilia/Hemostasis Centres in Canada. mcpoon@ucalgary.ca
authors.forename: M C
authors.initials: MC
authors.lastname: Poon
authors.forename: R
authors.initials: R
authors.lastname: d'Oiron
authors.forename: I
authors.initials: I
authors.lastname: Hann
authors.forename: C
authors.initials: C
authors.lastname: Négrier
authors.forename: L
authors.initials: L
authors.lastname: de Lumley
authors.forename: A
authors.initials: A
authors.lastname: Thomas
authors.forename: A
authors.initials: A
authors.lastname: Karafoulidou
authors.forename: C
authors.initials: C
authors.lastname: Demers
authors.forename: A
authors.initials: A
authors.lastname: Street
authors.forename: A
authors.initials: A
authors.lastname: Huth-Kühne
authors.forename: P
authors.initials: P
authors.lastname: Petrini
authors.forename: E
authors.initials: E
authors.lastname: Fressinaud
authors.forename: M
authors.initials: M
authors.lastname: Morfini
authors.forename: L
authors.initials: L
authors.lastname: Tengborn
authors.forename: A
authors.initials: A
authors.lastname: Marquès-Verdier
authors.forename: R
authors.initials: R
authors.lastname: Musso
authors.forename: O
authors.initials: O
authors.lastname: Devecioglu
authors.forename: D S
authors.initials: DS
authors.lastname: Houston
authors.forename: S
authors.initials: S
authors.lastname: Lethagen
authors.forename: C
authors.initials: C
authors.lastname: Van Geet
authors.forename: M
authors.initials: M
authors.lastname: von Depka
authors.forename: C
authors.initials: C
authors.lastname: Berger
authors.forename: P
authors.initials: P
authors.lastname: Beurrier
authors.forename: H A
authors.initials: HA
authors.lastname: Britton
authors.forename: W
authors.initials: W
authors.lastname: Gerrits
authors.forename: C
authors.initials: C
authors.lastname: Guthner
authors.forename: S
authors.initials: S
authors.lastname: Kuhle
authors.forename: J J
authors.initials: JJ
authors.lastname: Lorenzo
authors.forename: P E
authors.initials: PE
authors.lastname: Makris
authors.forename: N
authors.initials: N
authors.lastname: Nohe
authors.forename: P
authors.initials: P
authors.lastname: Paugy
authors.forename: B
authors.initials: B
authors.lastname: Pautard
authors.forename: M F
authors.initials: MF
authors.lastname: Torchet
authors.forename: N
authors.initials: N
authors.lastname: Trillot
authors.forename: M
authors.initials: M
authors.lastname: Vicariot
authors.forename: J
authors.initials: J
authors.lastname: Wilde
authors.forename: M
authors.initials: M
authors.lastname: Winter
authors.forename: H
authors.initials: H
authors.lastname: Chambost
authors.forename: J
authors.initials: J
authors.lastname: Ingerslev
authors.forename: M
authors.initials: M
authors.lastname: Peters
authors.forename: G
authors.initials: G
authors.lastname: Strauss
mesh_terms: D003029:Coagulants / Q000627:therapeutic use; D005167:Factor VII / Q000627:therapeutic use*; D015942:Factor VIIa; D005260:Female; D006801:Humans; D008297:Male; D017713:Platelet Transfusion / Q000009:adverse effects; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000188:drug therapy / Q000628:therapy; D011994:Recombinant Proteins / Q000627:therapeutic use*; D013915:Thrombasthenia / Q000175:diagnosis / Q000188:drug therapy* / Q000628:therapy
chemical_list: D003029:Coagulants; D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa